- Home
- NVCR
NVCR
NovoCure Limited
as 05-30-2025 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.9B | IPO Year: | 2015 |
| Target Price: | $32.83 | AVG Volume (30 days): | 941.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.17 - $34.13 | Next Earning Date: | 07-24-2025 |
| Revenue: | $621,711,000 | Revenue Growth: | 18.27% |
| Revenue Growth (this year): | 5.56% | Revenue Growth (next year): | 9.15% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | May 3 '25 | Sell | $17.91 | 592 | $10,604.20 | 83,556 | |
| Weinberg Uri | NVCR | Chief Innovation Officer | Mar 3 '25 | Sell | $18.67 | 4,905 | $92,020.26 | 166,822 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 3 '25 | Sell | $18.54 | 2,527 | $46,841.23 | 143,673 | |
| Cordova Ashley | NVCR | Chief Executive Officer | Mar 3 '25 | Sell | $18.54 | 2,053 | $38,055.02 | 204,005 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Mar 3 '25 | Sell | $18.54 | 250 | $4,634.08 | 83,556 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Business Wire
13 hours ago
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Motley Fool
4 days ago
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
Business Wire
5 days ago
Novocure Announces Upcoming Investor Events
Zacks
16 days ago
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
Zacks
a month ago
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Motley Fool
a month ago
Why NovoCure Stock Skyrocketed This Week
Motley Fool
a month ago
Why NovoCure Stock Leaped 4% Higher Today
Zacks
a month ago
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.